Safety and Efficacy Phase 2 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children

Pediatric Growth Hormone Deficiency Clinical Trial

Official title:
Safety and Dose Finding Study of Different MOD-4023 Dose Levels Compared to Daily r-hGH Therapy in Pre-pubertal Growth Hormone Deficient Children

Status Completed

Clinical Trial Summary

This is a phase II, open label, active-controlled, randomized safety and dose finding study of different MOD-4023 dose levels compared to daily r-hGH therapy in pre-pubertal growth hormone deficient children.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Pediatric Growth Hormone Deficiency

Clinical Trial Details

NCT number	NCT01592500
Study type	Interventional
Source	OPKO Health, Inc.
Contact
Status	Completed
Phase	Phase 2
Start date	February 2012
Completion date	July 2015

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT01718041` - Versartis Trial in Children to Assess Long-Acting Growth Hormone	Phase 1/Phase 2
Terminated	`NCT02068521` - Versartis Long-Term Safety Study of Somavaratan	Phase 2/Phase 3
Not yet recruiting	`NCT05509894` - Korean Post-marketing Surveillance Ngenla® Pre-filled Pen Injection for the Treatment of Pediatric Patients With Growth Disturbance Due to Insufficient Secretion of Growth Hormone
Completed	`NCT04633057` - A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency	Phase 3
Withdrawn	`NCT06113952` - A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth Hormone
Active, not recruiting	`NCT02968004` - Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children	Phase 3
Terminated	`NCT02413138` - Versartis Trial in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD) to Assess Long-Acting Growth Hormone (Somavaratan, VRS-317)	Phase 2/Phase 3